ImmunoPrecise Antibodies Ltd. (IPA): Price and Financial Metrics
IPA Price/Volume Stats
| Current price | $2.07 | 52-week high | $5.90 |
| Prev. close | $2.09 | 52-week low | $1.70 |
| Day low | $1.95 | Volume | 14,182 |
| Day high | $2.14 | Avg. volume | 58,475 |
| 50-day MA | $2.24 | Dividend yield | N/A |
| 200-day MA | $3.35 | Market Cap | 51.85M |
IPA Stock Price Chart Interactive Chart >
IPA POWR Grades
- IPA scores best on the Sentiment dimension, with a Sentiment rank ahead of 92.25% of US stocks.
- IPA's strongest trending metric is Stability; it's been moving up over the last 177 days.
- IPA's current lowest rank is in the Quality metric (where it is better than 5.65% of US stocks).
IPA Stock Summary
- IMMUNOPRECISE ANTIBODIES LTD's stock had its IPO on December 31, 2020, making it an older stock than merely 10.13% of US equities in our set.
- With a year-over-year growth in debt of 178.99%, IMMUNOPRECISE ANTIBODIES LTD's debt growth rate surpasses 93.75% of about US stocks.
- The volatility of IMMUNOPRECISE ANTIBODIES LTD's share price is greater than that of 85.54% US stocks with at least 200 days of trading history.
- Stocks that are quantitatively similar to IPA, based on their financial statements, market capitalization, and price volatility, are LEU, CSGS, SOFO, NTGR, and INTZ.
- Visit IPA's SEC page to see the company's official filings. To visit the company's web site, go to www.immunoprecise.com.
IPA Price Target
For more insight on analysts targets of IPA, see our IPA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $16.17 | Average Broker Recommendation | 1.5 (Moderate Buy) |
ImmunoPrecise Antibodies Ltd. (IPA) Company Bio
ImmunoPrecise Antibodies Ltd. engages in the antibody production and related services in the United States, Canada, Europe, and internationally. Its services include B cell sorting, screening and sequencing; custom, immune, and naive phage display production and screening; transgenic animals and multispecies antibody discovery; bi-specific, tri-specific, VHH, and VNAR (shark) antibody manufacturing; DNA cloning, protein and antibody downstream processing, purification in gram scale levels, and characterization and validation; antibody engineering; transient and stable cell line generation; antibody optimization and humanization; hybridoma production with screening and clone-picking; cryopreservation; affinity measurements, functional assays, and epitope mapping and binning; and modeling, design, and manufacturing of custom antigen. The company has a collaboration with University of Victoria to develop a saliva-based antibody-based test for the detection and screening of COVID-19; Zymeworks Inc. for the development of multiple antibody candidates to fight COVID-19; and National Research Council of Canada's Human Health Therapeutics Research Centre to develop neutralizing PolyTope antibodies against SARS-CoV-2, as well as a research partnership with Mila. ImmunoPrecise Antibodies Ltd. was founded in 1989 and is headquartered in Fargo, North Dakota.
Latest IPA News From Around the Web
Below are the latest news stories about IMMUNOPRECISE ANTIBODIES LTD that investors may wish to consider to help them evaluate IPA as an investment opportunity.
ImmunoPrecise Antibodies Announces CFO TransitionVICTORIA, British Columbia, September 19, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), today announced that it has accepted the resignation of Brad McConn, CFO, effective September 29, 2023. IPA has named Kristin Taylor, MBA, CPA, as interim Chief Financial Officer. |
IPA Reports Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024VICTORIA, British Columbia, September 14, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an AI-driven biotherapeutic research and technology company, today announced financial results for first quarter fiscal year 2024, which ended July 31, 2023. |
IPA to Report Financial Results and Recent Business Highlights for First Quarter Fiscal Year 2024 on September 14, 2023VICTORIA, British Columbia, September 08, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today announced that it will host a conference call to discuss its quarterly results and recent business highlights for first quarter fiscal year 2024, on Thursday, September 14, 2023, at 10:30 am Eastern Time. The financial results will be issued in a press release prior to the call. |
IPA Announces Board RefreshmentVICTORIA, British Columbia, September 05, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, is pleased to announce that further to its news release dated August 9, 2023, it has appointed, in its search for optimal Board composition, Barry A. Springer, Dirk Witters and Chris Buyse to the Board of Directors of the Company. |
IPA Responds to 13D FilingVICTORIA, British Columbia, August 09, 2023--IPA (IMMUNOPRECISE ANTIBODIES LTD.) (the "Company" or "IPA") (NASDAQ: IPA), an advanced biotherapeutic research and technology company, today issued the following statement in response to the Schedule 13D filing made on July 7, 2023 by Ingalls & Snyder, LLC a New York-based investment manager. |
IPA Price Returns
| 1-mo | -0.48% |
| 3-mo | -34.81% |
| 6-mo | -30.07% |
| 1-year | -58.60% |
| 3-year | -77.67% |
| 5-year | N/A |
| YTD | -60.27% |
| 2022 | -2.80% |
| 2021 | -64.15% |
| 2020 | 579.08% |
| 2019 | N/A |
| 2018 | N/A |
Loading social stream, please wait...